These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

620 related items for PubMed ID: 12427142

  • 1. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y, Bárány P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ, European/Australian NESP 970200 Study Group.
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Dec; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 7. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Dec; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW, Chang CH.
    Perit Dial Int; 2009 Dec; 29(2):199-203. PubMed ID: 19293358
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
    Macdougall IC, Matcham J, Gray SJ, NESP 960245/246 Study Group.
    Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
    Hörl WH, Holzer H, Mayer GJ, Osterreichische Aranesp Studiengruppe.
    Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):967-71. PubMed ID: 12635463
    [Abstract] [Full Text] [Related]

  • 12. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct 30; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 13. [Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO)].
    Del Vecchio L, Villa G, Carraro G, Morosetti M, Pedrini L, Adorati Menegato M, Amato M, Mauro MM, Borgatti P, Malberti F, Marai P, Locatelli F, Gruppo Di Studio NESP 2000 0116 (NESP 3b).
    G Ital Nefrol; 2004 Oct 30; 21(3):259-66. PubMed ID: 15285005
    [Abstract] [Full Text] [Related]

  • 14. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY, Chu TS, Huang JW, Wu MS, Wu KD.
    J Formos Med Assoc; 2008 Nov 30; 107(11):843-50. PubMed ID: 18971153
    [Abstract] [Full Text] [Related]

  • 15. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C, Terrat JC, Dumoulin A, Ang KS, Gassia JP, Chedid K, Maurice F, Canaud B, Conference Medical Group.
    Ann Pharmacother; 2009 Feb 30; 43(2):228-34. PubMed ID: 19407262
    [Abstract] [Full Text] [Related]

  • 16. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease.
    Suranyi MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R.
    Am J Nephrol; 2003 Feb 30; 23(2):106-11. PubMed ID: 12481149
    [Abstract] [Full Text] [Related]

  • 17. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ.
    Nephrol Dial Transplant; 2004 Apr 30; 19(4):898-903. PubMed ID: 15031347
    [Abstract] [Full Text] [Related]

  • 18. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Apr 30; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 19. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.
    Clin Nephrol; 2007 Mar 30; 67(3):140-8. PubMed ID: 17390738
    [Abstract] [Full Text] [Related]

  • 20. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
    Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P.
    J Am Med Dir Assoc; 2007 Feb 30; 8(2):83-90. PubMed ID: 17289537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.